title: Establishing schedules for repeated doses of strontium and for concurrent chemotherapy in hormone-resistant patients with prostate cancer: measurement of blood and urine strontium levels.
abstract: Strontium-89 (Sr-89) alone or with concurrent chemotherapy has a role in the treatment of patients with prostate cancer (PCP). The schedules for repeated doses of Sr-89 or for concurrent chemotherapy is undetermined. The objective of this study was to measure the effective half-life (Te) of Sr-89 using a detector available in a nuclear research facility. Blood and urine samples obtained from PCP treated with Sr-89 (Metastron, Amersham, U.K.) were measured for radioactivity with a High Pure Germanium (HPGe) detector in a gamma spectrometry system (Eurisys, France). Twenty-five urine and 22 blood samples were obtained from 8 patients during a period of 160 days after Metastron injection. Sr-89 radioactivity levels in blood and urine were quite low (<8.2 x 10(-3) microCi/mL) in all patients after 21 days, whereas Sr-85 (available in 0.5% of Metastron) urine and, to a lesser extent, blood radioactivity levels were moderately high and could be detected up to 160 days. Based on Sr-85 urine levels, the calculated Sr-89 Te ranged from 9.6 to 20.7 days. Sr-89 Te can be routinely calculated in PCP based on HPGe detection of Sr-85 radioactivity levels in urine. This measurement can establish schedules for either repeated doses of Sr-89 or concurrent chemotherapy.
authors.affiliation: Radiotherapy Unit, Division of Oncology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. rby@tasmc.health.gov.il
authors.forename: Rami
authors.initials: R
authors.lastname: Ben-Yosef
authors.forename: Omer
authors.initials: O
authors.lastname: Pelled
authors.forename: Rachel
authors.initials: R
authors.lastname: Marko
authors.forename: Akiva
authors.initials: A
authors.lastname: Vexler
authors.forename: Avi
authors.initials: A
authors.lastname: Teshuva
authors.forename: Uzi
authors.initials: U
authors.lastname: German
authors.forename: Moshe
authors.initials: M
authors.lastname: Levita
authors.forename: Rina
authors.initials: R
authors.lastname: Kol
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D004334:Drug Administration Schedule; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D019275:Radiopharmaceuticals / Q000097:blood / Q000627:therapeutic use / Q000652:urine; D013326:Strontium Radioisotopes / Q000097:blood / Q000627:therapeutic use* / Q000652:urine
chemical_list: D019275:Radiopharmaceuticals; D013326:Strontium Radioisotopes